Company:  EYEPOINT PHARMACEUTICALS, ... (EYPT)
Form Type:  10-Q
Filing Date:  8/6/2021 
CIK:  0001314102 
Address:  480 PLEASANT STREET
SUITE B300
 
City, State, Zip:  WATERTOWN, Massachusetts 02472 
Telephone:  617-926-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.53  
Change: 
0.02 (0.19%)  
Trade Time: 
Aug 05  
Market Cap: 
$358.52M
Trade EYPT now with 

© 2022  
Description of Business
We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. Our pipeline leverages our proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration ("wet AMD"), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ®, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application ("sNDA") strategy.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1.Unaudited Financial Statements
        BALANCE SHEET
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      FINANCIAL STATEMENTS
        CASH FLOW
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    PART II: OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
  EXHIBIT 32.2